Skip to main content

Table 3 Incidence of CMV disease and asymptomatic CMV infection in D+/R− transplants according to era after HTx

From: Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients

Era Prophylaxis CMV disease, n (%) Asymptomatic CMV infection, n (%) No CMV, n (%)
1988–1991 (n = 18) No 12 (67) 5 (28) 1 (5)
1992–1997 (n = 17) Pre-emptivea 13 (76) 3 (18) 1 (6)
1998–2000 (n = 11) Universalb 5 (46) 3 (27) 3 (27)
Total (n = 46)   30 (65) 11 (24) 5 (11)
  1. aPre-emptive treatment, monitoring with qualitative CMV PCR once weekly or two weeks apart for the first three months post-transplantation b1,000 mg of oral ganciclovir tid for 14 weeks